SCHEMBL3634346

SCHEMBL3634346

COC(=O)CC1c2cc(O)ccc2S(=O)(=O)N1c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 2/20 0.55
APOBEC3A P31941 1/20 0.47
DUSP3 P51452 1/20 0.47
PTPN5 P54829 1/20 0.47
PTPN11 Q06124 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
MAPT P10636 2/20 0.42
ATM Q13315 2/20 0.42
CACNA1G O43497 3/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.39
TDP1 Q9NUW8 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766960 0.88 CTDSP1 (0.53) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3763174 0.88 CTDSP1 (0.50) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3763396 0.87 CTDSP1 (0.52) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3634049 0.87 CTDSP1 (0.52) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3768510 0.87 CTDSP1 (0.54) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3773365 0.87 CTDSP1 (0.62) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3634652 0.84 CTDSP1 (0.52) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3769135 0.84 CTDSP1 (0.50) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3767808 0.82 CTDSP1 (0.56) CTDSP1APOBEC3ADUSP3PTPN5PTPN11
SCHEMBL3764079 0.80 CTDSP1 (0.45) CTDSP1APOBEC3ADUSP3PTPN5PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents INHIBOX LTD. (GB) 2010-12-09 US disclosed
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents INHIBOX LTD. (GB) 2010-12-09 US disclosed
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents INHIBOX LTD. (GB) 2010-12-09 US disclosed
EP-2155703-A1 BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Inhibox Ltd. (GB) 2010-02-24 EP disclosed
WO-2008142376-A1 BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS INHIBOX LTD. (GB) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents TNF, CS, COASY CTDSP1 725/4885APOBEC3A 3215/4885DUSP3 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.